Weiss Ratings Reaffirms “Sell (E+)” Rating for Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics (NASDAQ:FOLD)‘s stock had its “sell (e+)” rating reiterated by equities research analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Several other equities research analysts have also weighed in on the stock. Morgan Stanley raised shares of Amicus Therapeutics from an “equal weight” rating to an “overweight” rating in a report on Thursday, July 17th. Wall Street Zen raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, September 20th. Zacks Research raised shares of Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday. Finally, Needham & Company LLC raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a report on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Amicus Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $15.78.

Amicus Therapeutics Trading Up 0.1%

Shares of FOLD stock opened at $8.27 on Wednesday. The firm has a fifty day moving average of $7.71 and a 200-day moving average of $6.90. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.29 and a current ratio of 3.21. Amicus Therapeutics has a 52-week low of $5.51 and a 52-week high of $12.65. The stock has a market cap of $2.55 billion, a price-to-earnings ratio of -68.91 and a beta of 0.56.

Institutional Trading of Amicus Therapeutics

Hedge funds have recently bought and sold shares of the stock. Diversified Trust Co grew its stake in shares of Amicus Therapeutics by 2.2% during the 1st quarter. Diversified Trust Co now owns 83,542 shares of the biopharmaceutical company’s stock worth $682,000 after acquiring an additional 1,784 shares during the period. Tempus Wealth Planning LLC grew its stake in shares of Amicus Therapeutics by 7.2% during the 1st quarter. Tempus Wealth Planning LLC now owns 29,513 shares of the biopharmaceutical company’s stock worth $241,000 after acquiring an additional 1,990 shares during the period. CANADA LIFE ASSURANCE Co boosted its stake in Amicus Therapeutics by 2.8% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 83,764 shares of the biopharmaceutical company’s stock worth $480,000 after purchasing an additional 2,263 shares during the period. Stephens Inc. AR boosted its stake in Amicus Therapeutics by 27.4% in the 1st quarter. Stephens Inc. AR now owns 13,655 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 2,938 shares during the period. Finally, Osaic Holdings Inc. boosted its stake in Amicus Therapeutics by 450.1% in the 2nd quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 3,358 shares during the period.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.